Novel integrase inhibitors are in advanced clinical development, and cross-resistance data are needed to consider the possibility to plan a sequential usage within this class of antiretroviral drugs. Ex vivo phenotypic assays were conducted on 11 wild-type and 27 fully replicating recombinant viruses obtained from 11 patients failing previous raltegravir-containing regimens. Dolutegravir maintained its activity in vitro on viruses with mutations in position 143 and 155. However, viruses with mutation Q148R associated with secondary mutations and the combination Q148H1G140S were instead associated with a reduced level of susceptibility to dolutegravir in vitro.
Integrase strand transfer inhibitors (INSTIs) have demonstrated an effective activity against human immunodeficiency virus (HIV) type 1 infection [1] . Lack of cross-resistance with other compounds belonging to different classes of antiretrovirals has demonstrated that raltegravir (RAL), the first INSTI approved, is highly effective in achieving viral suppression when combined with an optimized background regimen even in experienced patients [1, 2] . Given the potency and safety of INSTIs, these drugs were tested and also proved to be effective in treatment-naive patients [1, 2] . The second INSTI investigational compound in advanced clinical development, elvitegravir (ELV), has been shown to be potent in early clinical trials, although it requires pharmacological boosting [1] . Dolutegravir ([DTG] S/GSK1349572) is in the early stages of clinical development, but it showed strong antiviral activity in a 10-day monotherapy pilot trial and in phase IIb trials including treatment-naive patients [3] (http://jac. oxfordjournals.org/content/65/12/2485.long). Furthermore, DTG has a long half-life, allowing once-daily dosing without pharmacological boosting, thus being an interesting compound for clinical use [3] .
Viral variants resistant to RAL or ELV have been detected in patients failing INSTI-based regimens [4, 5] . In particular, amino acid substitutions proximal to the catalytic core domain have first been described in RAL-resistant variants that belong to 3 main pathways: the Y143 R/C, the N155H, and the Q148 K/R/H pathways. Although the mutations selected at each of these key positions are associated with therapy failure, a complex evolving pattern of primary and secondary resistance mutations has been documented during treatment [5, 6] . Additional mutations associated with resistance to RAL have been reported, including V72I, L74M, E92Q, T97A, E138 A/K, G140 S/A, V151I, E157Q, G163 R/K, and D232N [4, 6, 7] . Failure to ELV was most often associated with selection of the E92Q, Q148 R/H/K, and N155H mutations accompanied by other secondary mutations such as H51Y, T66I/A/K, V72I, Q95K, E138K, G140 C/S, S147G, E157Q, and S230R [1, 4] . For both compounds, the mutation pattern evolves toward a progressive increase in drug resistance [1, 5, 7] .
Recent data generated using site-directed mutants [8] and in vivo pilot studies [9] have suggested that HIV-1 with primary mutations at codon 155 or codon 143 remain susceptible in vitro to DTG and viruses that have the 148 mutation, and additional mutations have less decreased susceptibility to this compound. Although initial DTG resistance data have been reported for RAL-resistant clinical isolate virus populations [10] , there remains a need for additional phenotypic data on DTG susceptibility of clonal samples derived from patients failing RAL treatment. Methods Phenotypic analyses were conducted on 38 (including 11 wildtype) recombinant viruses obtained from 11 HIV-1 (clade B)-infected patients failing previous RAL-containing regimens. Plasma samples were collected and stored at 280°C before RAL initiation, at time of failure, and later if RAL was maintained. All patients had been enrolled in the RAL Expanded Access Program (MK0518-023) and had responded to the RAL regimen with at least 1 log reduction of viremia levels. Resistance to RAL was evaluated according to Stanford database report. After informed consent was obtained from all patients, viral RNA was extracted using QIAamp viral RNA mini kit (Qiagen). Only 1 sample at a time was processed, and clinical samples and all amplification steps were conducted with a limiting dilution strategy to minimize artificial recombination events. The integrase region (codons 1-301) was targeted, using the following nested reverse transcription-polymerase chain reaction (RT-PCR) protocol and the following primers: Int1F, 5#-CATGGGTACCAGCA-CACACAAAGG-3# and Int1R, 5#-CCATGTTCTAATCCT-CATCCTGTC-3# for the first PCR round; and primers Int2F, 5#-GGAATTGGAGGAAATGAACAAGTAGAT-3# and Int2R, 5#-GCCACACAATCATCACCTGCCATC-3# for the second PCR round. The first nested RT-PCR reaction was performed in 50 lL using the SuperScriptTM III Platinum High-Fidelity One-Step qRT-PCR System (Invitrogen) with the following thermal profile: 30 minutes at 50°C and 10 minutes at 95°C for 1 cycle, 1 minute at 95°C, 1 minute at 52°C, and 1 minute and 10 seconds at 72°C for 50 cycles, followed by 10 minutes at 72°C. The nested reaction was performed in 100 lL using PCR SuperMix High Fidelity (Invitrogen) and the following thermal profile: 10 minutes at 95°C for 1 cycle, 1 minute at 95°C, 1 minute at 50°C, and 1 minute and 10 seconds at 72°C for 30 cycles, followed by 10 minute at 72°C [6] . Amplified products were cloned into pNL(AD8)DeltaInt proviral vector [7] . Individual clones were then sequenced using an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems) (GenBank accession numbers: JN163873-JN163910). Recombinant fully replicating viruses were generated after transfection of 293T cells using Fugene6 Transfection reagent (Roche), following the manufacturer's instructions.
All phenotypic assays were performed on freshly purified CD4 1 T cells obtained from healthy blood donors (informed consent available) as described previously [7] . Peripheral blood mononuclear cells were obtained by Hystopaque-Ficoll gradient centrifugation, activated with phytohemagglutinin (0.5 mg/mL) and interleukin 2 (100 U/mL) for 3 days. Then, CD4 1 T cells were purified by magnetic beads (Miltenyi Biotec) and immediately used to evaluate drug activity. Virus titer was determined by infecting CD4 1 cells seeded in 96-microwell plates with serial dilution of viruses. After 10 days, p24 production (AAlto Bio Reagents) was quantified and virus titer was determined according to the Karber formula. Drug susceptibility was evaluated in triplicate and repeated 3 times as described previously [7] . DTG was kindly provided by ViiV Healthcare, and RAL was provided by the National Institutes of Health AIDS reagents repository (https://www.aidsreagent.org/ Index.cfm). For each analysis, CD4
1 T cells were collectively infected with 100 the median tissue culture infective dose of each recombinant virus. After 4 hours of infection, cells were washed with phosphate-buffered saline twice and seeded in 96-well plates (100 000 cells/well). Ten RAL or DTG serial dilutions (from 0.16 lM to 360 lM) were then added to the cultures.
After 5 days, supernatant was recovered and viral p24 was quantified. The inhibition curves were then fitted by nonlinear regression with GraphPad Prism software, allowing IC 50 calculation (drug concentration giving 50% infectivity inhibition). Resistance fold change (FC) for each variant was calculated by dividing the IC 50 of each RAL-resistant clone by that for the baseline sample obtained from each patient always tested in parallel [7] .
Results and Discussion Susceptibility to DTG was obtained for 27 distinct combinations of primary and secondary mutations associated with a wide range of resistance levels to RAL (IC 50 FC, 5.23-700; Table 1 and Figure 1 ). Variants with mutations at position 143 (Y143 S/K/C/ R/G) alone or in combination with the secondary mutation T97A were not influenced in their susceptibility to DTG, with no difference from baseline values (FC, 0.63-1.53). No impact on DTG FC could be observed when variants bearing the N155H mutation (even in combination with mutation Y143R) were tested. Otherwise, a heterogeneous level of resistance to DTG was observed for variants containing mutations at position 148. In fact, the FC values varied from 3 (Q148R1E138K) to 27 (E138A1G140S1Y143H1Q148H). Interestingly, the combination Q148H1G140S, the most frequent pathway associated with RAL failure, was associated with variable levels of susceptibility to GSK1349572 only in part due to the combination of secondary mutations associated. These data are consistent with previous DTG susceptibility reported with clinical isolates from subjects experiencing virologic failure during RAL therapy [10] . The Tyr143 and Asn155 pathway isolates had wildtype DTG susceptibility, and Gln148 pathway isolates had broader and higher DTG FC. The data are also consistent with the VIKING phase IIB study [9] treating subjects with RALresistant virus with 50 mg of DTG once or twice a day in cohorts I and II, respectively. In cohort II (DTG twice a day), the day 11 primary endpoint response for Tyr143 or Asn155 pathway virus was equivalent to the Gln148 pathway [9] . However, in cohort I (DTG once a day), subjects with Tyr143 or Asn155 pathway virus and Gln14811 RAL pathway virus (G140S, Q148H) had better day 11 responses than subjects with Gln1481 $2 [9] . Our data are also substantially in agreement with other previously published in vitro data [2, 8] . However, in these cases, it cannot be excluded that the genetic background of the integrase gene of the HIV-1 mutant circulating in each patient modulates the overall level of susceptibility to DTG associated with this major pathway (Table 1 ). Substitutions at integrase codons 101, 124, and 153 have been observed during in vitro passage in the presence of DTG [8] . Of note, none of our clones had those substitutions at position 153. Patients 3, 4, 8, and 11 had the T124A polymorphism, and patients 2, 5, 6, 10, and 11 had the L101I polymorphism since before RAL initiation and apparently without effects on DTG susceptibility.
Both RAL and DTG inhibit the same step of the integrase process with a similar mechanism; however, they have different dissociation rates and structural characteristics [11] . The different interactions of DTG and RAL with the residues present in the active site of the enzyme may explain, in part, the lack of a complete overlap in the resistance profile observed with the 2 integrase inhibitors (INIs). Mutations in position 148 and 140 are located at the basis of the loop present in the catalytic-core domain, which is essential for enzyme function and are thus more deeply located and able to interact directly with both drugs. Mutations in position 155 and 143 are more distinctly located from the drug binding site and may interact mainly with RAL large side residues and much less with the more compact DTG molecule [11] . From a clinical perspective, the present study shows that variants selected at the latest time points are indeed not only more resistant to RAL, but they also showed a reduced susceptibility to DTG in vitro. These data may suggest a higher genetic barrier for this compound. However, we must also underline that because the specific pattern of resistance mutations that may arise after DTG treatment in INIs-naive patients is not known, these observations cannot be conclusive.
Overall, availability of DTG may significantly enrich the novel class of INSTIs, with the potential to be fully effective also in many of the patients failing other INSTI-containing regimens. In fact, RAL and ELV are largely cross-resistant, even if development of the E92Q mutation is more commonly associated with ELV compared with RAL, and mutations at position Tyr143 were only observed with RAL at failure and not with ELV (consistently with in vitro data showing limited resistance to ELV conferred by this pattern) [12] . The overlap of the INSTI resistance patterns selected by ELV and RAL will make sequencing from ELV to RAL (or vice versa) unlikely to be successful [12] . Moreover, the genotype of RAL or ELV-resistant viruses was shown to evolve under continuous treatment with INSTIs, driving the selection of variants with higher resistance level and restored replication capacity that, in some rare cases, coincides with a pathway shift toward the Q148H1G140S combination, if this was not selected immediately at RAL or ELV failure [4, 7, 13] .
In this scenario, however, there is still a reasonable hope that a prompt genotypic monitoring at INSTI failure may preserve this novel class of drugs in those patients selecting only viruses with the Tyr143 or the Tyr155 pathways, allowing a sequential usage of INIs. Several points may support this hypothesis, such as the high genetic barrier for the combination associated with crossresistance (Q148H1G140S) requiring at least 2 transversions and 1 transition for subtype B viruses [2] . Moreover, the high selectivity advantage of the Q148H1G140S variants under RAL treatment would rapidly allow these variants to predominate if present in minority variants and thus be promptly identified. Both of these factors made the sequential usage of NNRTI unsuccessful in the past, where minority variants carrying cross-resistance associated mutations with low genetic barrier and little impact on virus fitness were rapidly selected when the second drug was introduced [14] . Nevertheless, a rapid reversion (complete or partial) of RAL and ELV associated resistance mutations occurs in the majority of cases, including in the patients described in this study (data not shown) requiring an accurate historical genotype of the integrase gene before starting a DTG treatment [15] . Thus, we cannot exclude that archived cross-resistant variants are present in the reservoirs.
Finally, we still do not know a clinical DTG FC cutoff value that will be associated with therapy failure, or what level of in vitroreduced DTG susceptibility caused by the various RAL resistance genotypic pathways will be associated with no or partial clinical efficacy. 
Notes

